The Food and Drug Administration (FDA) has recently provided instructions to Covid vaccine manufacturers regarding the target for next fall’s Covid vaccines. The FDA signaled that it would prefer manufacturers to update the strain in their vaccines to a version of the virus that is currently circulating broadly, LP.8.1.
The instructions were given to the manufacturers of approved Covid-19 vaccines, advising them to target monovalent JN.1-lineage-based Covid-19 vaccines (2025-2026 Formula) for use in the United States beginning in fall 2025, preferably using the LP.8.1 strain. This decision follows recommendations from the World Health Organization and the European Medicine’s Agency to update to the LP.8.1 version of the virus.
During a meeting of the Vaccines and Related Biological Products Advisory Committee, members appeared split on whether manufacturers should update their vaccine targets. Some expressed concerns that a strain change could lead to new testing requirements that might delay vaccine delivery for the fall. However, the committee unanimously voted to target a JN.1 version of the SARS-CoV-2 virus for the 2025-2026 vaccine.
The publication of a new Covid vaccine regulatory framework proposed by FDA Commissioner Marty Makary and Vinay Prasad has raised additional questions. The framework suggests that Covid vaccines may only be available to high-risk individuals and calls for new randomized controlled trials to assess the benefits of vaccination in younger, healthy adults. This could potentially delay the availability of updated vaccines.
Manufacturers like Moderna and Pfizer-BioNTech, which use messenger RNA technology with short production time, are anticipated to move to the LP.8.1 strain. However, Novavax, which requires more lead time for production, expressed a preference for sticking with the JN.1 virus used in their 2024-2025 vaccine.
The meeting of the Vaccines and Related Biological Products Advisory Committee marked the first time since the start of the Trump administration that the committee was allowed to meet. The FDA’s decision to update vaccine targets for the fall comes as the agency navigates the evolving landscape of Covid vaccination and strives to ensure timely availability of vaccines while maximizing protection against the virus. Transparency in the approval process for Covid vaccines is crucial in building trust and confidence among the public. This was emphasized by Monto, a professor emeritus in the University of Michigan’s School of Public Health, during a recent meeting. Prasad had already left the meeting at that point, while Kaslow remained non-committal, suggesting that the topic of transparency could be considered for discussion at a future VRBPAC meeting.
In a related development, the FDA has mandated that Pfizer and Moderna include expanded warning labels on their Covid vaccine products. The warning is specifically for the risk of myocarditis, an inflammation of the heart muscle, which is a rare side effect associated with the vaccines. This side effect has been predominantly observed in teenage boys, as well as in individuals who have contracted Covid. Reports of myocarditis following Covid vaccination were most prevalent in the initial stages of the vaccine rollout, particularly when individuals received two doses of the vaccine within a short interval of three to four weeks. However, recent data presented to the CDC’s expert panel indicates a significant decrease in reports of myocarditis post-vaccination since the year 2021.
It is important to note a correction in an earlier version of this story, which erroneously stated that the European Medicines Agency allowed vaccine manufacturers to choose which version of the Covid virus to target. This misinformation has been rectified to ensure accuracy in reporting.
The continuous monitoring and evaluation of Covid vaccine safety and efficacy remain a top priority for regulatory authorities and health organizations. With ongoing updates and improvements in labeling and transparency, the public can make informed decisions about their health and well-being. Stay informed, stay safe.
